Atopic Dermatitis

The FDA has accepted Dermavant Science’s supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged 2 years and older, the company announced in a press release.

AbbVie reported a worldwide net revenue of $12.31 billion in the first quarter of 2024 despite Humira sales dropping due to biosimilar competition, according to a company press release.

Healio has compiled April’s most-read news in dermatology.

Dupilumab demonstrated sustained effectiveness across patientreported outcome measures in adult and pediatric individuals with atopic dermatitis, according to a study.

Incyte and Escient Pharmaceuticals have entered a definitive agreement under which Incyte will acquire Escient for $750 million, the companies announced in a press release.

Adults and adolescents with moderate to severe atopic dermatitis treated with upadacitinib reported year-long improvements in skin symptoms, mental health and quality of life, according to a study.

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.

WASHINGTON — Using dupilumab to treat children with moderate to severe atopic dermatitis proved effective, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The use of a noninvasive skin tape strip at age 2 months can identify infants who are at risk for developing food allergy later, according to a study published in The Journal of Allergy and Clinical Immunology.

As spring begins, patients with tree, grass and weed allergies may have to cope with oral allergy syndrome, which arises from an allergic reaction to certain fresh or raw foods, including vegetables, fruits and nuts, a specialist said.